PharmaMar has partnered with Globant to accelerate cancer drug discovery through a new multi-agent artificial intelligence framework. Developed using Globant Enterprise AI, the system delivers over 90% accuracy in complex data retrieval and generates insights up to 15 times faster, enabling researchers to identify high-potential drug candidates more efficiently.

The platform analyses vast volumes of scientific, clinical and regulatory data, supporting decision-making across PharmaMar’s R&D ecosystem. More than 20 specialised digital agents operate across preclinical, clinical, regulatory, commercial and strategic functions, working within a secure architecture to process documents, simulate scenarios and rank promising pharmaceutical assets.

The system can review over 4,500 research documents and prioritise the 10 most viable treatment-indication combinations from more than 8,000 possibilities—tasks that would previously have taken months. By integrating internal databases with external sources, including FDA and EMA data, the platform enables faster, data-driven decisions.

Beyond improving speed and precision, the collaboration strengthens knowledge reuse and advances digital innovation across PharmaMar, with future plans to expand into hypothesis generation and automated scientific reporting.